Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Avalo Therapeutics has raised $431.3M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
Avalo Therapeutics's investors include RA Capital Management, TCG Crossover, OrbiMed, Commodore Capital, Deep Track Capital.
Avalo Therapeutics is headquartered in Rockville, United States.
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Avalo Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Avalo Therapeutics — Funding & Investors." VCBacked, May 5, 2026, https://www.vcbacked.co/company/avalo-therapeutics. Accessed November 7, 2026.
VCBacked. (2026). Avalo Therapeutics — Funding & Investors. Retrieved November 7, 2026, from https://www.vcbacked.co/company/avalo-therapeutics
{{cite web |title=Avalo Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/avalo-therapeutics |website=VCBacked |access-date=November 7, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Avalo Therapeutics? Request a listing update